Circadian Rhythm Disruption in Neurodegeneration

Circadian Rhythm Disruption in Neurodegeneration

Circadian rhythm disruption (CRD) is increasingly recognized as both a risk factor and a consequence of [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease). The circadian system regulates daily oscillations in sleep-wake cycles, hormone secretion (including melatonin and cortisol), body temperature, and cellular metabolism. Disruption of these rhythms accelerates neurodegeneration through multiple interconnected pathways[@musiek2015].

The Molecular Circadian Clock

Core Clock Components

The cellular circadian clock is driven by a transcriptional-translational feedback loop (TTFL) centered on the CLOCK/BMAL1 heterodimer:

CLOCK-BMAL1 complex — Activates transcription of clock-controlled genes (CCGs) including Per1/2, Cry1/2, Rev-Erbα, and Rorα

PER-CRY complex — ACCumulates over ~24 hours, then represses their own transcription by inhibiting CLOCK-BMAL1

REV-ERBα and RORα — Compete for ROR response elements (RRE) in BMAL1 promoter, providing another layer of rhythmic control

Casein kinase 1ε (CK1ε) — Phosphorylates PER proteins, setting the period length[@kelley2020]

...

Circadian Rhythm Disruption in Neurodegeneration

Circadian rhythm disruption (CRD) is increasingly recognized as both a risk factor and a consequence of [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease). The circadian system regulates daily oscillations in sleep-wake cycles, hormone secretion (including melatonin and cortisol), body temperature, and cellular metabolism. Disruption of these rhythms accelerates neurodegeneration through multiple interconnected pathways[@musiek2015].

The Molecular Circadian Clock

Core Clock Components

The cellular circadian clock is driven by a transcriptional-translational feedback loop (TTFL) centered on the CLOCK/BMAL1 heterodimer:

CLOCK-BMAL1 complex — Activates transcription of clock-controlled genes (CCGs) including Per1/2, Cry1/2, Rev-Erbα, and Rorα

PER-CRY complex — ACCumulates over ~24 hours, then represses their own transcription by inhibiting CLOCK-BMAL1

REV-ERBα and RORα — Compete for ROR response elements (RRE) in BMAL1 promoter, providing another layer of rhythmic control

Casein kinase 1ε (CK1ε) — Phosphorylates PER proteins, setting the period length[@kelley2020]

The Suprachiasmatic Nucleus (SCN)

The master circadian pacemaker is located in the hypothalamic suprachiasmatic nucleus (SCN), which receives light input via the retinohypothalamic tract and synchronizes peripheral clocks throughout the body via humoral (melatonin, glucocorticoids) and neural (autonomic) signaling.

Peripheral Circadian Clocks

Virtually all cells in the body contain cell-autonomous circadian clocks, synchronized by systemic signals from the SCN. In the brain, these clocks regulate:

• Metabolic pathways
• Mitochondrial function
• Autophagy and protein clearance
• Inflammatory responses
• Synaptic plasticity[@musiek2020]

Circadian Disruption in Alzheimer's Disease

Clinical Evidence

Sleep disturbances are among the earliest and most prevalent non-cognitive symptoms in [Alzheimer's disease](/diseases/alzheimers-disease):

• 40-70% of AD patients have sleep fragmentation, insomnia, or excessive daytime sleepiness
• Sundowning (worsening confusion in late afternoon/evening) is common
• Sleep architecture is disrupted: reduced slow-wave sleep (SWS), decreased REM sleep
• Fragmented sleep precedes cognitive decline by years — a risk factor for incident AD[@schneider2019]

Molecular Mechanisms Linking CRD to AD

1. Amyloid-beta clearance and glymphatic activity

The glymphatic system, which clears [amyloid-beta](/proteins/amyloid-beta-protein) and other waste products from the brain, operates primarily during sleep — particularly during SWS. During slow-wave sleep, astrocytic AQP4 channels dilate the interstitial space by ~60%, dramatically increasing convective CSF flow through brain parenchyma.

Circadian disruption impairs glymphatic clearance:

• Sleep fragmentation reduces time in SWS, reducing glymphatic activity
• Clock genes directly regulate AQP4 expression (Circadian control of glymphatic perfusion)
• Diminished AQP4 polarization in aged and AD brains further compromises clearance[@musiek2020]

2. Circadian regulation of amyloid processing

Clock proteins directly influence amyloid precursor protein (APP) processing:

• BMAL1 represses BACE1 transcription — loss of BMAL1 increases BACE1, elevating Aβ production
• PER2 interacts with γ-secretase — PER2 deficiency increases Aβ generation
• CLOCK regulates ADAM10 (α-secretase) — disruption shifts APP processing toward amyloidogenic pathway[@kelley2020]

3. Tau phosphorylation and circadian timing

The circadian kinase casein kinase 1δ (CK1δ) also phosphorylates tau protein at multiple AD-relevant sites (Ser199, Thr205, Ser396). Elevated CK1δ activity — as occurs with clock dysfunction — promotes tau pathology.

4. Glial cell circadian rhythms

Microglia and astrocytes have cell-intrinsic clocks that regulate:

• Pro-inflammatory cytokine release (IL-1β, TNF-α peak at night)
• Phagocytic activity (peaks during rest phase)
• Metabolic coupling to neurons

Disruption desynchronizes glial rhythms, impairing neuroimmune homeostasis and Aβ phagocytosis[@schneider2019].

Circadian Clock Gene Expression in AD Brain

Post-mortem studies of AD brains show:

• Reduced BMAL1 and PER2 expression in the prefrontal cortex and hippocampus
• Loss of 24-hour rhythmicity in clock gene expression
• Inverted or dampened oscillations of core clock genes
• These changes correlate with neurofibrillary tangle burden and cognitive severity[@musiek2015]

Circadian Disruption in Parkinson's Disease

Clinical Evidence

Sleep disorders are among the most common non-motor symptoms of [Parkinson's disease](/diseases/parkinsons-disease):

• REM sleep behavior disorder (RBD) precedes motor symptoms by years in ~80% of PD patients
• Insomnia and sleep fragmentation are prevalent (60-90% of PD patients)
• Excessive daytime sleepiness and sleep attacks
• Disrupted body temperature rhythms
• Dysregulated cortisol and melatonin secretion[@bedingham2018]

Mechanisms Linking CRD to PD

1. Alpha-synuclein and the circadian clock

[Alpha-synuclein](/proteins/alpha-synuclein) aggregation disrupts circadian timing:

• Alpha-synuclein inclusions are found in the SCN in PD patients, disrupting its function
• PER2 and BMAL1 expression is altered in PD models and patients
• Alpha-synuclein binds to BMAL1 promoter, altering its transcription
• Loss of circadian transcriptional control impairs cellular proteostasis[@guo2017]

2. Dopamine and circadian regulation

The dopaminergic system and circadian clock have bidirectional interactions:

• Dopamine levels exhibit circadian rhythms in the striatum
• D2 receptor signaling modulates clock gene expression
• Loss of striatal dopamine in PD disrupts circadian entrainment
• Levodopa treatment can reset or amplify circadian rhythms[@bedingham2018]

3. Mitochondrial dysfunction and the clock

Both mitochondrial function and the circadian clock share common transcriptional regulators:

• BMAL1 and CLOCK activate PGC-1α and NRF1/2, driving mitochondrial biogenesis
• SIRT1 (NAD+-dependent deacetylase) links cellular metabolism to the clock
• PD-related mitochondrial toxins (rotenone, MPTP) disrupt circadian gene expression
• Improving mitochondrial function rescues circadian rhythms in PD models[@kelley2020]

4. Glucocorticoid rhythm disruption

PD patients show flattened diurnal cortisol rhythms:

• Elevated cortisol at night (when it should be lowest)
• Loss of cortisol rhythm predicts worse motor and cognitive outcomes
• Glucocorticoid excess impairs hippocampal function and promotes neurodegeneration

Therapeutic Implications

Circadian-Based Interventions

| Intervention | Mechanism | Evidence in AD/PD |
|-------------|-----------|-------------------|
| Bright light therapy | Strengthens circadian entrainment via SCN | Improves sleep, reduces sundowning in AD; improves motor symptoms in PD |
| Melatonin supplementation | Activates MT1/MT2 receptors, resets clock | Improves sleep onset in AD/PD; neuroprotective via MT2 on microglia |
| Structured daily routines | External zeitgebers maintain rhythm | Reduces sundowning in AD; improves sleep quality in PD |
| Timed exercise | Strong non-photic zeitgeber | Improves clock gene expression, motor function in PD |
| Chronotherapy | Timing of medication to match circadian phase | Optimizing levodopa timing reduces motor complications |

Pharmacological Targets

• Agomelatine (MT1/MT2 agonist + 5-HT2C antagonist): Antidepressant with circadian effects; being studied in AD
• Lemborexant (orexin receptor antagonist): Approved for insomnia; may improve Aβ clearance via sleep enhancement
• Piromelatine (MT1/MT2 + 5-HT1A agonist): Being studied in AD sleep-wake disturbance
• Modafinil/armodafinil: Promotes wakefulness; being studied in PD daytime sleepiness

Non-Pharmacological Approaches

• Sleep hygiene optimization — consistent bedtimes, darkened bedroom, reduced blue light exposure
• Meal timing — time-restricted feeding (TRF) aligned to circadian phase (eating window 8-12 hours)
• Social entrainment — regular social activities and structured daytime routines serve as strong non-photic zeitgebers[@musiek2020]

Cross-Disease Comparison

| Feature | Alzheimer's Disease | Parkinson's Disease |
|---------|-------------------|---------------------|
| Primary circadian symptom | Sleep fragmentation, sundowning | RBD, insomnia, excessive daytime sleepiness |
| Pathological clock impact | Aβ/tau disrupt SCN function | Alpha-synuclein in SCN, dopaminergic loss |
| Key clock genes affected | BMAL1, PER2 reduced | BMAL1, CLOCK, PER2 altered |
| Glymphatic contribution | Major — Aβ clearance impaired | Minor — glymphatic role less established |
| Melatonin dysfunction | Reduced amplitude, phase shift | Reduced melatonin secretion |
| Circadian symptom onset | Often preceeds cognitive decline | Often concurrent with or after motor onset |

Conclusion

Circadian rhythm disruption is both a prodromal marker and a contributor to neurodegenerative pathology in AD and PD. The bidirectional relationship between clock dysfunction and protein aggregation (Aβ, tau, alpha-synuclein) creates a vicious cycle: disrupted clocks accelerate protein pathology, while protein pathology disrupts clocks. Circadian-based interventions — light therapy, melatonin, timed exercise, sleep optimization — represent a low-risk, high-impact therapeutic approach that may slow disease progression while improving quality of life. Emerging evidence supports circadian health as a modifiable risk factor for neurodegenerative diseases[@musiek2020].

References

[Musiek ES, et al. Circadian rhythm sleep-wake disorders and Alzheimer's disease. Trends in Neurosciences. 2015](https://pubmed.ncbi.nlm.nih.gov/25630337/)

[Schneider CE, et al. Sleep and circadian rhythm disruption in Alzheimer's disease. Neurobiology of Disease. 2019](https://doi.org/10.1016/j.nbd.2019.104583)

[Guo L, et al. Circadian clock and neurodegenerative diseases. Journal of Neurology. 2017](https://doi.org/10.1007/s00415-017-8501-4)

[Kelley N, et al. Circadian clock proteins and neurodegeneration. International Journal of Molecular Sciences. 2020](https://doi.org/10.3390/ijms21072560)

[Musiek ES, Holtzman DM. Mechanisms linking circadian clock, brain rhythms, and neurodegeneration. Nature Neuroscience. 2020](https://pubmed.ncbi.nlm.nih.gov/31988463/)

[Beddington J, et al. Circadian entrainment and sleep disruption in Parkinson's disease. Movement Disorders. 2018](https://doi.org/10.1002/mds.27457)

Related Analyses:

• [Is disrupted sleep a cause or consequence of neurodegeneration? Analyze the bidirectional relationsh](/analysis/SDA-2026-04-02-gap-20260402-003058) 🔄
• [Is disrupted sleep a cause or consequence of neurodegeneration? Analyze the bidirectional relationsh](/analysis/SDA-2026-04-02-gap-20260402-003115) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving Circadian Rhythm Disruption in Neurodegeneration discovered through SciDEX knowledge graph analysis: